TMCnet News
Affimed to Present at Upcoming Investor ConferencesHeidelberg, Germany, February 21, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to improving patient outcomes through the power of the innate immune system, today announced that Dr. Adi Hoess, Chief Executive Officer, will present at the following upcoming investor conferences:
About Affimed N.V. Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company that engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat cancers. For more information, please visit www.affimed.com. Affimed Investor Contact: Affimed Media Contact: |